Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma

Loading news article.

Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma | WAPE

Reported Earlier, HUTCHMED Gains China Approval For ATLED (Fanregratinib) As Confirmatory Phase IIIb Trial Enrollment Continues For FGFR2-Positive Cholangiocarcinoma

Article summary

Related companies

Comments —